

Progress in Blood Disorders and Transfusion

Antony Methal^{*}

Department of Hematology, University of Khartoum, Khartoum, Sudan

DESCRIPTION

I'm gratified to specify that during the mid-year 2021, the Journal of Blood Disorders & Transfusion (JBDT) has effectively released its twelth volume and has delivered 4 issues respectively. Journal of Blood Disorders & Transfusion is an scholarly journal that focuses on all aspects of molecular genetics, pathophysiology and epidemiology as well as prevention, diagnosis, and management of blood disorders with current state of research in the field of transfusion medicine, hematology, hemato-oncology, pediatric hematology, laboratory hematology, neuropathy, blood donors, thalassemia, bone marrow transplantation, anti-HBc, haemodilution, hemodialysis, blood stem cell, blood disorders, Rh factor, blood cancer, platelet disorders, hemolytic anemia etc. Alongside these it's an International Standard Serial Number (ISSN) as 2155-9864. In excess of 50 well prominent experts all through the world were acting as Board of editorial for our journal. More than 400 articles were submitted which incorporate Review, research articles, case reports, short communications and so forth. In a normal the article acknowledgment or dismissal will be educated to writer inside 21 to 30 days of initial submission while the preliminary quality check result will be recognized inside 24 to 48 hours of early submission. For simple contact of authors, JBDT has given whatsapp contact number in our home page so that authors can contact easily for any questions or concerns to editorial assistant. Editorial, Review, and Manuscript tracking system was introduced for easy tracking of the manuscript by author, editor as well as publisher. Authors can track their manuscript easily by utilizing provided credentials during the

period of submission. In 2020 JBDT is endeavor to procure quality articles identified with blood cancer, lupus, neutropenia, red blood cells, white blood cells, plasma cell disorders etc. In 2020, JBDT has picked to utilize person to person communication (social networking platform) stage like twitter, LinkedIn to have simple connection with editors, reviewers, authors, as well as public and eminent experts. The new issues with respect to blood disorder consideration are posting on regular routine in twitter. Also we might want to thank our readers for their help. We are having in excess of 2000 readers worldwide and this will be just conceivable with open access journal. Our journal gives its Google examination report and the visitor's traffic is the standard for the accomplishment of any logical journal and the JBDT is continually drawing in watchers across the world. Readers from the significant nations including Japan, United States, Japan, United Kingdom, Saudi Arabia, India, Egypt, and Pakistan visit our journal area to find out about the on-going exploration exercises in this domain. For its forthcoming volume of JBDT, we will give similar highlights much the same as 2020 and with the author's support and analysts work we will go further with each issue for a month throughout the year and with more help from Editorial group we will attempt coin extraordinary issue identified with the subject of our Journal. Indeed I might likewise want to offer my thanks to all authors, reviewers, the publisher, the advisory and the editorial board of JBDT, the workplace conveyors for their help in bringing out one more volume and anticipate their tenacious help to draw out the Volume 12 issue 5 of JBDT in planned time. We guarantee the entirety of the readers that we do our level best in this long term.

Correspondence to: Antony Methal, Department of Hematology, University of Khartoum, Khartoum, Sudan, E-mail: methantony@yahoo.com

Received: June 08, 2021; Accepted: June 22, 2021; Published: June 29, 2021

Citation: Methal A (2021) Progress in Blood Disorders and Transfusion. J Blood Disord Transfus. 12: e126.

Copyright: © 2021 Methal A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.